Search Results

The Cardiovascular Sonospectrographic Analyzer (CSA) is intended for use in health care environments and setting where conventional stethoscopes (both electronically augmented and non-augmented) and phonocardiographs are used by health care professionals for the auscultation, graphical representation, measurement and archiving of cardiovascular, pulmonary, and other such sounds, both normal and abnormal, as produced by the human body. The CSA is a medical instrument intended for use by, or at the direction of, a qualified health care professional as a diagnostic aid for the clinical assessment and discrimination of acoustic patterns relating to or caused by clinically significant pathologies and medical conditions as known, defined, or specified in standard medical auscultation/phonocardiographic reference textbooks, peer review journals, and medically approved auscultation training materials. The CSA is further intended for the monitoring of interventional or prophylactic therapies that are susceptible to the level of medical efficacy provided by CSA and as is clinically indicated at the discretion of the physician. The CSA is also intended for use in telemedical applications where medical acoustic experts are indicated or desired.

Limitations on Intended Use: The CSA is not intended for use on a singular basis for delivery of health care, not as a standalone diagnostic aid for evaluation of cardiovascular conditions and pathologies for which other more suitable diagnostic tools or medical procedures are available or indicated.

The Cardiovascular Sonospectrographic Analyzer (CSA) is a cardiovascular acoustic detection system. The CSA is a passive, non-invasive means of detecting, processing and displaying human physiologic acoustic data as an aide/adjunct to the clinician in diagnosing conditions. It is useable in all applications where clinicians have traditionally used the stethoscope. However, through the use of ultra-sensitive acoustic detection technology, digital signal processing and a Fast Fourier Transform (FFT), the CSA is able to detect, process and display physiologic acoustic signals from the human body that are as little as 1,000,000 times less than the peak acoustic energy level of a heart sound.

Here's an analysis of the provided text regarding the acceptance criteria and study for the Cardiovascular Sonospectrographic Analyzer (CSA):

Based on the provided document, the Cardiovascular Sonospectrographic Analyzer (CSA) is presented as substantially equivalent to its predicate device, the Transmedica Digital Electronic Stethoscope (DES) (510(k) 963418). The core argument for acceptance is this substantial equivalence rather than a new clinical study demonstrating specific performance metrics against pre-defined acceptance criteria.

The document heavily emphasizes that the CSA's primary advancements are in automating the analysis process and improving the efficiency of software for displaying derived data, while the underlying hardware and signal processing techniques (Fast Fourier Transform) remain essentially the same as the predicate device.

Acceptance Criteria and Reported Device Performance

• RF Emissions: CISPR-11/IEC-601-1-2 (modified) UL 2601
• Magnetic Fields: RE101(mod) MIL-STD-461D
• Electrostatic Discharges (Immunity): IEC 801-2
• Radiated EM Fields (Immunity): IEC 601-1-2 (modified)
• AC Voltage Fluctuations Transients and Surges: Guidelines per Para. (M) (7) and sub-para.C (2) |
  | Mechanical and Environmental Safety | Compliance with Standards/Specifications: The device performs according to:
• Controls Protection: Company design specifications
• Connector Protective: Company design specifications
• Mechanical Safety: Company design specifications
• Vibration and Shock Resistance: Company design specifications
• Fluid Spill Resistance: IEC-601 (44.6) IEC 529
• Temperature and Humidity: Company design specifications
• Surface Temperature: Company design specifications
• Toxic Materials: No toxic materials from the device come into contact with the patient or operator during use |
  | Intended Use Safety & Effectiveness (implied) | Claimed Safety and Effectiveness: "Does not use any form of radiation, contains no physical properties or features that present a risk, use no chemicals and has no design elements that also manifest a risk, it is further concluded that it is safe and effective for its intended use." This is based on substantial equivalence and lack of new risks compared to the predicate. |

Study Information

The document does not describe a new clinical study to prove the device meets performance acceptance criteria in terms of diagnostic accuracy or clinical outcomes. Instead, it relies on the concept of substantial equivalence to a previously cleared predicate device.

Here's why no specific information is provided for points 2-9:

1. Sample size used for the test set and the data provenance: Not applicable, as no new clinical performance study is described. The document states that "the clinical data acquired by the DES is 100% compatible with the CSA and data acquired by the CSA is fully backwards compatible and can be processed and analyzed using the DES software," suggesting data from the predicate could be used, but no new test set performance data is reported.
2. Number of experts used to establish the ground truth for the test set and the qualifications of those experts: Not applicable, as no new clinical performance study is described.
3. Adjudication method for the test set: Not applicable, as no new clinical performance study is described.
4. If a multi-reader multi-case (MRMC) comparative effectiveness study was done, If so, what was the effect size of how much human readers improve with AI vs without AI assistance: Not applicable. The device is not presented as an AI-assisted diagnostic tool that improves human reader performance in a controlled MRMC study. Its primary advancement is automating the visualization of data derived from an existing, cleared technology. The document describes it as a "diagnostic aid" for "clinical assessment and discrimination of acoustic patterns" rather than an AI with a specific "effect size" on human performance.
5. If a standalone (i.e. algorithm only without human-in-the-loop performance) was done: Not applicable. The device is explicitly described as an adjunct: "as an aide/adjunct to the clinician in diagnosing conditions" and "not intended for use on a singular basis for delivery of health care, not as a standalone diagnostic aid."
6. The type of ground truth used (expert consensus, pathology, outcomes data, etc.): Not applicable, as no new clinical performance study is described.
7. The sample size for the training set: Not applicable. The device is a signal processing and display system, not a machine learning model that requires a distinct training set in the modern sense. Its "training" (development) was based on established scientific medical literature and techniques used in the predicate device.
8. How the ground truth for the training set was established: Not applicable for the reasons stated above. The system processes and displays signals, rather than being "trained" on a ground truth dataset in the way an AI model would be.

Summary of Approach:

The submission for the Cardiovascular Sonospectrographic Analyzer (CSA) relies entirely on a substantial equivalence (SE) argument. The acceptance criteria primarily revolve around demonstrating that the new device is as safe and effective as the predicate device by showing:

• Similar intended use.
• Similar technological characteristics (hardware is "essentially the same," core signal processing is identical).
• Differences (primarily software automation for display and analysis) do not raise new questions of safety or effectiveness.

No new clinical performance studies are described within this section of the 510(k) summary, as the submission aims to show "equivalence" rather than a novel claim requiring new clinical validation data.

Ask a specific question about this device